HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Michelot, J.M. Articles by Plagne, R.J. Search for Related Content PubMed PubMed Citation Articles by Michelot, J.M. Articles by Plagne, R.J.

Phase II Scintigraphic Clinical Trial of Malignant Melanoma and Metastases with Iodine-123-N-(2-Diethylaminoethyl 4-Iodobenzamide)

INSERM U 71, Clermont-Ferrand, France
CHU Gabriel Montpied, Clermont-Ferrand, France
Centre Antoine Lacassagne, Nice, France
Hôtel-Dieu, Clermont-Ferrand, France
CIS biointernational, Gif-Sur-Yvette, France

Correspondence: For correspondence or reprints contact: J.M. Michelot, MD, PhD, INSERM U 71, Rue Montalembert, B.P. 184, 63005 Clemont-Ferrand Cedex, France.

ABSTRACT

Preclinical studies established [¹²⁵I]-N-(2-diethylaminoethyl) 4-iodobenzamide (BZA) as a potential radiopharmaceutical in the management of patients with malignant melanoma. External detection of both murine and human melanotic melanomas was possible after intravenous injection of ¹²⁵I-BZA in tumor-bearing mice. This article reports a Phase II clinical trial evaluating ¹²³I-BZA as an imaging agent of primary melanomas and metastases. A total of 110 patients with a history of melanoma were investigated in two nuclear medicine departments. Subjects were imaged from 20 to 24 hr after the intravenous injection of 3.5 mCi (130 MBa) of ¹²³I-BZA. After injection, no short-term or long-term side effects were noted. Calculated on a lesion-site basis, diagnostic sensitivity was 81%, accuracy was 87% and specificity was 100%. The melanoma nature of previously occult lesions was confirmed by clinical criteria and/or additional investigations in follow-up studies. The scintigraphies were normal in 44 patients in clinical remission after treatment of malignant melanoma and in seven patients with nonmelanoma disease. No false positive results were observed. Iodine-123-BZA scintigraphy appears to be a safe and useful agent for the detection and follow-up of patients with malignant melanoma BZA also allowed the detection of unsuspected lesions and the evaluation of the results of various therapeutic procedures such as surgery, chemotherapy, immunobiology, biological therapy or radiotherapy.

This article has been cited by other articles:

				M. Rapp, J. C. Maurizis, J. Papon, P. Labarre, T.-D. Wu, A. Croisy, J. L. Guerquin-Kern, J. C. Madelmont, and E. Mounetou A New O6-Alkylguanine-DNA Alkyltransferase Inhibitor Associated with a Nitrosourea (Cystemustine) Validates a Strategy of Melanoma-Targeted Therapy in Murine B16 and Human-Resistant M4Beu Melanoma Xenograft Models J. Pharmacol. Exp. Ther., July 1, 2008; 326(1): 171 - 177. [Abstract] [Full Text] [PDF]

				T. Q. Pham, P. Berghofer, X. Liu, I. Greguric, B. Dikic, P. Ballantyne, F. Mattner, V. Nguyen, C. Loc'h, and A. Katsifis Preparation and Biologic Evaluation of a Novel Radioiodinated Benzylpiperazine, 123I-MEL037, for Malignant Melanoma J. Nucl. Med., August 1, 2007; 48(8): 1348 - 1356. [Abstract] [Full Text] [PDF]

				F. Chehade, C. de Labriolle-Vaylet, N. Moins, M.-F. Moreau, J. Papon, P. Labarre, P. Galle, A. Veyre, and E. Hindie Secondary Ion Mass Spectrometry as a Tool for Investigating Radiopharmaceutical Distribution at the Cellular Level: The Example of I-BZA and 14C-I-BZA J. Nucl. Med., October 1, 2005; 46(10): 1701 - 1706. [Abstract] [Full Text] [PDF]

				Z. Cheng, A. Mahmood, H. Li, A. Davison, and A. G. Jones [99mTcOAADT]-(CH2)2-NEt2: A Potential Small-Molecule Single-Photon Emission Computed Tomography Probe for Imaging Metastatic Melanoma Cancer Res., June 15, 2005; 65(12): 4979 - 4986. [Abstract] [Full Text] [PDF]